Endocrine Abstracts

Introduction: The treatment with tyrosine-kinase inhibitor drugs (1st line Lenvatinib) in patients with radioiodine-refractory differentiated thyroid cancer (I-131) and disease progression can be burdened by important side effects which often require suspension/reduction of the therapy and correct multidisciplinary management.Patients and methods: Clinical/histopathological characteristics, outcome, adverse events and the role of gender have been evaluat...